Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesChange in TaxesDeferred TaxesDepreciation & Amortization (CF)Depreciation and DepletionDivestmentsExchange Rate EffectFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Anika Therapeutics (ANIK) Cash from Financing Activities (2016 - 2025)

Historic Cash from Financing Activities for Anika Therapeutics (ANIK) over the last 16 years, with Q3 2025 value amounting to -$13000.0.

  • Anika Therapeutics' Cash from Financing Activities rose 9967.43% to -$13000.0 in Q3 2025 from the same period last year, while for Sep 2025 it was -$10.6 million, marking a year-over-year decrease of 5108.77%. This contributed to the annual value of -$12.7 million for FY2024, which is 10128.08% down from last year.
  • According to the latest figures from Q3 2025, Anika Therapeutics' Cash from Financing Activities is -$13000.0, which was up 9967.43% from $179000.0 recorded in Q2 2025.
  • Anika Therapeutics' Cash from Financing Activities' 5-year high stood at $667000.0 during Q4 2022, with a 5-year trough of -$7.0 million in Q3 2021.
  • For the 5-year period, Anika Therapeutics' Cash from Financing Activities averaged around -$1.9 million, with its median value being -$862000.0 (2022).
  • As far as peak fluctuations go, Anika Therapeutics' Cash from Financing Activities soared by 101166.67% in 2022, and later tumbled by 1064565.22% in 2023.
  • Anika Therapeutics' Cash from Financing Activities (Quarter) stood at $60000.0 in 2021, then soared by 1011.67% to $667000.0 in 2022, then plummeted by 48.73% to $342000.0 in 2023, then crashed by 1665.5% to -$5.4 million in 2024, then skyrocketed by 99.76% to -$13000.0 in 2025.
  • Its Cash from Financing Activities stands at -$13000.0 for Q3 2025, versus $179000.0 for Q2 2025 and -$5.4 million for Q1 2025.